CoChat

Novel clinical and radiomic predictors of rapid disease progression phenotypes among lung cancer patients treated with immunotherapy: An early report

Open access
Tunali, Ilke, Gray, Jhanelle E., Qi, Jin, Abdalah, Mahmoud, Jeong, Daniel K., Guvenis, Albert, Gillies, Robert J., Schabath, Matthew B. · 2019 · Lung Cancer
Cited by 144

The DOI matches its Crossref record; 11 of the 11 references it cites were found in a registry or an index.

Abstract

Objectives Immune-checkpoint blockades have exhibited durable responses and improved long-term survival in a subset of advanced non-small-cell lung cancer (NSCLC) patients. However, highly predictive markers of positive and negative responses to immunotherapy are a significant unmet clinical need. The objective of this study was to identify clinical and computational image-based predictors of rapid disease progression phenotypes in NSCLC patients treated with immune-checkpoint blockades. Materials and Methods Using time-to-progression (TTP) and/or tumor growth rates, rapid disease progression phenotypes were developed including hyperprogressive disease. The pre-treatment baseline predictors that were used to identify these phenotypes included patient demographics, clinical data, driver mutations, hematology data, and computational image-based features (radiomics) that were extracted from pre-treatment computed tomography scans. Synthetic Minority Oversampling Technique (SMOTE) was used to subsample minority groups to eliminate classification bias. Patient-level probabilities were calculated from final clinical-radiomic models to subgroup patients by progression-free survival (PFS). Results Among 228 NSCLC patients treated with single agent or double agent immunotherapy, we identified parsimonious clinical-radiomic models with modest to high ability to predict progression phenotypes with area under the receiver-operator characteristics ranging from 0.812 to 0.843. Patients who experienced TTP < 2 months or hyperprogressive disease were classified with 73.4% and 82.3% accuracy after SMOTE subsampling, respectively. When the patient subgroups based on patient-level probabilities were analyzed for survival outcomes, patients with higher probability scores had significantly worse PFS. Conclusions The models found in this study have potential important translational implications to identify highly vulnerable NSCLC patients treated with immunotherapy that experience rapid disease progression and survival poor outcomes.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1016/j.lungcan.2019.01.010

Cites

11 of 11 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 11 references

Cited by

See all 144

Metadata

Authors
Tunali, I., Gray, J. E., Qi, J., Abdalah, M., Jeong, D. K., Guvenis, A., Gillies, R. J., & Schabath, M. B.
Venue
Lung Cancer
Publisher
Elsevier BV
Published
2019-03
Volume
129
Pages
75-79
ISSN
0169-5002 (ISSN-L)
OpenAlex
W2914472860
Cited by
144
References
11
FWCI
13.65
Type
journal article
Language
en
Open access
bronze

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Novel clinical and radiomic predictors of rapid disease progression phenotypes among lung cancer patients treated with immunotherapy: An early report. https://app.cochat.ai/papers/10.1016/j.lungcan.2019.01.010
The paper
Tunali, I., Gray, J. E., Qi, J., Abdalah, M., Jeong, D. K., Guvenis, A., Gillies, R. J., & Schabath, M. B. (2019). Novel clinical and radiomic predictors of rapid disease progression phenotypes among lung cancer patients treated with immunotherapy: An early report. Lung Cancer. https://doi.org/10.1016/j.lungcan.2019.01.010

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.